Investment Rating - The report initiates coverage with a "Buy" rating for the company [9]. Core Insights - The company is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout, focusing on ADCs, antibodies, and recombinant protein drugs, primarily targeting oncology and age-related diseases [5][17]. - The ADC technology platform is advanced, with the Nectin-4 ADC expected to become a best-in-class (BIC) product, showing promising clinical results compared to existing therapies [6][9]. - The company has a robust pipeline of innovative drugs and biosimilars, with significant revenue growth projected from 2024 to 2026 [8][10]. Summary by Sections Company Overview - The company was established in 2017 and went public on the Shanghai Stock Exchange in 2022, focusing on the research, production, and sales of biopharmaceuticals [17]. - It has 16 products at various stages, including 12 innovative products and 4 biosimilars, with 3 products already on the market [17]. ADC Technology Platform - The company has developed a next-generation ADC targeted conjugation technology platform (IDDCTM), which includes proprietary technologies that enhance drug stability and efficacy [6][28]. - The Nectin-4 ADC (9MW2821) is the fastest progressing ADC in China for treating urothelial carcinoma, currently in Phase III clinical trials [6][9]. Innovative Product Pipeline - The company is advancing multiple differentiated targets, including 9MW1911 (for COPD) and 9MW3011 (for blood disorders), with significant global development progress [7][30]. - The biosimilars have begun commercializing, contributing to cash flow for innovative drug development [7][30]. Financial Projections - Revenue forecasts for 2024, 2025, and 2026 are projected at 2.09 billion, 8.51 billion, and 15.14 billion RMB, respectively, with significant year-on-year growth rates [8][10]. - The company expects to achieve a net profit margin improvement, with net losses decreasing from 1.09 billion RMB in 2024 to 258 million RMB in 2026 [10].

Financial Performance - Total revenue for 2024 reached RMB 19,878.57 million, a 55.50% increase compared to RMB 12,783.55 million in the previous year[3] - The company's net profit attributable to shareholders was RMB -106,691.89 million, with a basic earnings per share of RMB -2.67[3] - The company reported a weighted average return on equity of -51.67%, a decrease of 17.13 percentage points from -34.54% in the previous year[3] Assets and Equity - Total assets decreased by 4.45% to RMB 425,701.55 million from RMB 445,504.84 million[4] - Shareholders' equity attributable to the parent company decreased by 40.17% to RMB 154,593.85 million, with net asset value per share dropping by 40.19% to RMB 3.87[4] Revenue Drivers - The increase in revenue was primarily driven by significant sales growth of the drug Mai Li Shu® and the approval of Mai Wei Jian® in March 2024[5] Research and Development - The company maintained a high level of R&D investment as multiple innovative drugs are in critical trial stages[6] Operating Costs - Operating costs and sales expenses increased due to further market expansion and commercialization efforts[5] Financial Data Caution - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[7] - Investors are advised to be cautious due to potential investment risks associated with the preliminary financial data[7]

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 证券代码：688062 证券简称：迈威生物 公告编号：2025-006 迈威（上海）生物科技股份有限公司 第二届监事会第十五次会议决议公告 表决结果：3 票同意，0 票反对，0 票弃权。 具体内容详见与本公告同日刊登于上海证券交易所网站（www.sse.com.cn） 的《迈威（上海）生物科技股份有限公司关于继续使用部分暂时闲置募集资金 进行现金管理的公告》。 特此公告。 迈威（上海）生物科技股份有限公司 迈威（上海）生物科技股份有限公司（以下简称"公司"）第二届监事会 第十五次会议通知于 2025 年 1 月 17 日以书面方式送达全体监事，于 2025 年 1 月 22 日以现场结合通讯方式召开。会议由监事会主席楚键先生主持，会议应到 监事 3 人，实到监事 3 人。会议的召集、召开程序和方式符合《公司法》等法 律法规以及《迈威（上海）生物科技股份有限公司章程》（以下简称"公司章 程"）的有关规定，会议决议合法、有效。 二、监事会会议审议情况 （一 ...

海通证券股份有限公司 1 二、本次继续使用部分暂时闲置募集资金进行现金管理的基本情况 （一）投资目的 为提高募集资金使用效率，在不影响募投项目开展、募集资金使用计划和保 证募集资金安全的前提下，公司及全资子公司将合理利用部分暂时闲置募集资金 进行现金管理，提高募集资金使用效益、增加股东回报。 关于迈威（上海）生物科技股份有限公司 继续使用部分暂时闲置募集资金进行现金管理的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为迈威 （上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"）首次公开 发行股票并上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海 证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第11 号——持续督导》《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》等有关规定，对公司继续使用部分暂时闲置募集资金进行现金管理的事项 进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 12 月 7 日出具的《关于同意迈威 （ ...

Financial Performance - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -970 million and -1,160 million CNY, continuing the trend of losses compared to the previous year [2]. - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -1,000 million and -1,190 million CNY [2]. - The total profit for the previous year was -1,055.29 million CNY, with a net profit attributable to shareholders of the parent company at -1,053.43 million CNY [5]. - The company anticipates continued negative net profit attributable to shareholders of the parent company for the 2024 fiscal year [6]. Sales and Market Expansion - The company reported a significant increase in sales revenue due to market expansion, particularly from the drug Mai Li Shu®, which saw a substantial rise in sales compared to the previous year [6]. - The drug Mai Wei Jian® was approved for market launch in March 2024, contributing to increased sales revenue [6]. Operating Costs and R&D - Operating costs and sales expenses have increased in line with the expansion of commercialization efforts [6]. - The company maintains a high level of research and development investment, with multiple innovative drugs in critical trial stages [6]. Forecast Accuracy and Data Status - There are no significant uncertainties affecting the accuracy of this earnings forecast [7]. - The data provided is preliminary and subject to change, with final audited financial data to be disclosed in the 2024 annual report [8].

迈威（上海）生物科技股份有限公司 2024 年第四次临时股东大会会议资料 2024 年 12 月 | 目录 | | --- | | 2024 年第四次临时股东大会会议须知 | | 3 | | --- | --- | --- | | 年第四次临时股东大会会议议程 2024 | | 5 | | 2024 年第四次临时股东大会会议议案 | | 8 | | 议案一 关于公司于境外公开发行股票（H | 股）并在香港联合交易所有限公司 | | | 主板上市的议案 | | 8 | | 议案二 关于公司于境外公开发行股票（H | 股）并在香港联合交易所有限公司主 | | | 板上市方案的议案 | | 9 | | 议案三 关于公司转为境外募集股份有限公司的议案 | | 13 | | 议案四 关于公司境外公开发行 股募集资金使用计划的议案 H | | 14 | | 议案五 关于公司境外公开发行 H 股并上市决议有效期的议案 | | 15 | | 议案六 关于授权董事会及其获授权人士全权处理与本次境外首次公开发行 | | H | | 股并上市有关事项的议案 | | 16 | | 议案七 关于境外公开发行 H 股前滚存利润分配方式的 ...

Group 1 - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to meet funding needs and enhance internationalization [1] - The company is in discussions with intermediaries regarding the H-share issuance, with significant uncertainties regarding approval and implementation [1] - The company aims to leverage the national strategy for the western development to expand both domestic and international markets through a partnership with the Chongqing High-tech Zone Management Committee [1][4] Group 2 - The total planned investment for the bone health innovation drug project is 2 billion yuan, with the company investing no less than 1.6 billion yuan [2] - The project will be operated by the company's wholly-owned subsidiary, and the registered capital of this subsidiary will be increased from 20 million yuan to 1.008 billion yuan [2][3] - The investment will include contributions in the form of intangible assets, specifically the technology achievements of an already listed biological drug [2][3] Group 3 - The project will allow the subsidiary to become the marketing authorization holder for the drug, gaining rights for research, production, and commercialization [3] - The project aims to establish a national marketing center and conduct clinical research for expanding indications of the drug [3][4] - The local government will support the company's drug promotion and services, targeting over 1 million elderly individuals annually [4][5]

海通证券股份有限公司 关于迈威（上海）生物科技股份有限公司 预计2025年度日常关联交易的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为迈威 （上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"）首次公开 发行股票并上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指 引第11号——持续督导》《上海证券交易所科创板上市公司自律监管指引第1号— —规范运作》等有关规定，对公司预计2025年度日常关联交易事项进行了核查， 具体情况如下： 一、日常关联交易概况 （一）日常关联交易履行的审议程序 1、公司董事会审计委员会审议程序 公司于2024年12月10日召开第二届董事会审计委员会第十二次会议，通过了 《关于预计2025年度日常关联交易的议案》，并同意将该议案提交至公司董事会 审议。 2、公司董事会审议程序 公司于2024年12月15日召开第二届董事会第十五次会议，审议通过了《关于 预计2025年度日常关联交易的议案》，关联董事唐春山回避了相关事项的表决， 相关议案获出席会议的非关联董事一致表决通过。本 ...

迈威（上海）生物科技股份有限公司 第二届董事会提名委员会第二次会议的审核意见 经审阅公司第二届董事会非独立董事候选人 HAI WU（武海）先生、吴玉 峰先生的个人履历、教育背景等相关资料，未发现其存在《公司法》等法律法 规和《公司章程》中规定的不得担任公司董事的情形；未发现其存在被中国证 监会确定为市场禁入者且尚在禁入期的情形；未发现其存在被证券交易所公开 认定不适合担任上市公司董事的情形；最近 36 个月内未受过中国证监会行政处 罚；最近 36 个月内未受到证券交易所公开谴责或者 3 次以上通报批评；未因涉 嫌犯罪被司法机关立案侦查或者涉嫌违法违规被中国证监会立案调查，亦不存 在重大失信等不良记录，符合相关法律法规、规范性文件规定的董事任职资格 要求。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》《上市公司独立董事管理办法》《迈威（上海）生物科技股份有限公司章程》 （以下简称"《公司章程》"）等有关规定，迈威（上海）生物科技股份有限 公司（以下简称"公司"）第二届董事会提名委员会对第二届董事会独立董事 候 ...

证券代码：688062 证券简称：迈威生物 公告编号：2024-059 迈威（上海）生物科技股份有限公司 关于聘请 H 股发行及上市审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、拟聘会计师事务所的基本情况 （一）基本信息 安永香港为一家根据香港法律设立的合伙制事务所，由其合伙人全资拥有。 安永香港自1976年起在香港提供审计、税务和咨询等专业服务，为众多香港上市 公司提供审计服务，包括银行、保险、证券等金融机构。安永香港自成立之日起 即为安永全球网络的成员，与安永华明会计师事务所（特殊普通合伙）一样是独 立的法律实体。 （二）投资者保护能力 自2019年10月1日起，安永香港根据香港《会计及财务汇报局条例》注册为 公众利益实体核数师。此外，安永香港经中华人民共和国财政部核准取得在中国 内地临时执行审计业务许可证，并是在美国公众公司会计监督委员会 （USPCAOB）和日本金融厅（Japanese Financial Services Authority）注册从事相 关审计业务的会计师事务 ...